We would like to cordially invite you to the 2nd EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit to be held from 20-22 September 2018 in Geneva, Switzerland.
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed.
More information to come soon.
Partnership opportunities are available for the NAFLD summit 2018. For full details contact us.
Prof. Elisabetta Bugianesi
Prof. Philip N. Newsome
Prof. Vlad Ratziu